At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 280 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study To Investigate The Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
In Brief
A Phase 2 clinical trial evaluating Placebo and CP-690,550 for Crohn's Disease. Completed, enrolled 280 participants across 140 sites in 18 countries.
Detailed Summary
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one dose of the tested drug is more effective than placebo (inactive drug).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
CountriesAustralia, Austria, Bulgaria, Canada, Croatia, Czechia, France, Germany, Greece, Hungary, Israel, Japan, Netherlands, South Africa, South Korea, Spain, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartOct 2011
Primary CompletionFeb 2015
Study CompletionMar 2015
TodayJul 2026
First PostedJul 13, 2011
Enrollment StartOct 1, 2011
Primary CompletionFeb 1, 2015
Study CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.0 years ago
Interventions
Placebodrug
oral tablets twice daily
CP-690,550drug
oral tablets twice daily
CP-690,550drug
oral tablets twice daily